Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Dec 01, 2015 9:28am

174 Views

Post# 24342077

RE:RE:RE: Zenith Epigenetics Appoints Dr. Norman C.W. Wong to the B..

Hi GV.

I wonder about the significance of the departure of Dr Peter Johann? It seems to me to be a loss. Perhaps he will still be involved at RVX?

Press release doesn't explain why Dr Johann is leaving and this makes me suspicious.

Glad to see Dr Wong recognized.

SH is very slow today.
Toinv

Bullboard Posts

How one company is disrupting PoC testing